Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
CervoMed Inc. reported that it received a notice of allowance from the United States Patent and Trademark Office for a new patent covering its drug candidate neflamapimod. The patent protects use of neflamapimod to treat dementia with Lewy bodies in patients without substantial Alzheimer’s disease-like tau pathology and is expected to provide intellectual property protection into 2042, strengthening long-term exclusivity for this indication.
CervoMed Inc. reported that it received a notice of allowance from the United States Patent and Trademark Office for a new patent covering its drug candidate neflamapimod. The patent protects use of neflamapimod to treat dementia with Lewy bodies in patients without substantial Alzheimer’s disease-like tau pathology and is expected to provide intellectual property protection into 2042, strengthening long-term exclusivity for this indication.
Joshua S. Boger filed Amendment No. 2 to his Schedule 13D on CervoMed Inc., reporting beneficial ownership of 2,204,143 shares of common stock, or 19.99% of the outstanding shares, based on 11,026,233 shares of common stock outstanding.
His position includes shares held directly, through the JSB 2021 Trust and ASB 2021 Trust, as well as stock options and a limited amount of warrant shares constrained by a 19.99% maximum ownership limitation. The filing also reflects participation by the JSB 2021 Trust in a June 11, 2026 private placement of 955,414 units, each priced at $3.14 and including common stock plus Series B and Series C warrants.
CervoMed Inc. director-associated trusts participated in a significant private placement. On June 11, 2026, the Joshua S. Boger 2021 Trust purchased 955,414 units at $3.14 per unit in a private placement, each unit consisting of one share of common stock plus one Series B warrant and one Series C warrant.
The Series B warrants have a $3.32 exercise price and expire five years from issuance, while the Series C warrants have a $3.14 exercise price and expire one year from issuance. After these transactions, trusts for which Joshua S. Boger is sole trustee hold 1,600,117 and 195,748 common shares, respectively, though he disclaims beneficial ownership of these securities.
CervoMed Inc. furnished an update that investor presentation materials about its business, clinical studies, development plans and financial position are available on its website under the Investors – Events and Presentations section. The company notes these materials may be used in meetings with investors, analysts and others.
The information is provided under Regulation FD as furnished, not filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced.
CervoMed Inc. director Frank Zavrl received a grant of stock options as part of his non-employee director compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of common stock at an exercise price of $2.91 per share under the 2025 Equity Incentive Plan. These options vest monthly in substantially equal 1/12th increments over one year beginning June 30, 2026, contingent on his continued board service. Following this grant, Zavrl holds 8,150 stock options directly.
CervoMed Inc. director Marwan Sabbagh reported receiving a grant of stock options as part of his board compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share. These options were granted under the company’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The options vest in substantially equal monthly installments over one year, with 1/12 of the underlying shares vesting on the last day of each month beginning June 30, 2026, contingent on his continued board service.
CervoMed Inc. director David Quigley received a stock option grant as part of his compensation for joining the board. On June 8, 2026, he was awarded options to buy 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share, expiring on June 8, 2036.
The grant was made under the company’s 2025 Equity Incentive Plan and its non-employee director compensation policy. The underlying shares vest in substantially equal 1/12 monthly installments over one year, starting June 30, 2026, subject to his continued board service.
CervoMed Inc. reported that director Jeffrey V. Poulton received a stock option award tied to his election to the board. On June 8, 2026, he was granted options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share.
The award was granted under CervoMed’s 2025 Equity Incentive Plan pursuant to its non-employee director compensation policy. The underlying shares vest in substantially equal monthly installments over one year, with 1/12 of the award vesting on the last day of each month beginning on June 30, 2026, subject to his continued service.
CervoMed Inc. director Jane H. Hollingsworth received a stock option grant tied to her election to the board. The award covers 8,150 shares of CervoMed common stock with an exercise price of $2.91 per share and expires on June 8, 2036.
The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares vest monthly over one year in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, contingent on continued board service.
CervoMed Inc. director and 10% owner Sylvie Gregoire received a stock option grant related to her election to the board. The award covers 8,150 shares of common stock at an exercise price of $2.91 per share and expires on June 8, 2036. The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares will vest in 12 equal monthly installments on the last day of each month starting June 30, 2026, contingent on her continued board service.